王 爽,郑秀艳,孙文华,陈俊华,毛奎艳.阿托伐他汀联合依折麦布对冠心病患者氧化应激及血脂水平的影响[J].,2017,17(13):2470-2473 |
阿托伐他汀联合依折麦布对冠心病患者氧化应激及血脂水平的影响 |
Effects of Ezetimibe and Atorvastatin on Oxidative Stress and Blood Lipid Levels of Patients with Coronary Heart Disease |
投稿时间:2016-12-11 修订日期:2016-12-29 |
DOI:10.13241/j.cnki.pmb.2017.13.018 |
中文关键词: 冠心病 氧化应激 血脂 依折麦布 阿托伐他汀 |
英文关键词: Coronary heart disease Oxidative stress Blood lipid Ezetimibe Atorvastatin |
基金项目:辽宁省科技攻关计划项目(2011225038) |
|
摘要点击次数: 455 |
全文下载次数: 232 |
中文摘要: |
摘要 目的:探讨依折麦布联合阿托伐他汀对冠心病患者氧化应激及血脂水平的影响及临床疗效。方法:选择2013年8月-2016年8月于我院接受治疗的冠心病患者144例,随机分为对照组和研究组,每组72例。对照组患者给予阿托伐他汀及硝酸甘油治疗,研究组患者给予阿托伐他汀和依折麦布治疗。观察并比较两组患者治疗前后血清过氧化物酶(MPO)、丙二醇(MDA)、超氧化物歧化酶(SOD)、总胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白(LDL-C)及高密度脂蛋白(HDL-C)水平、心功能及临床疗效。结果:研究组患者临床总有效率(87.5%)效显著高于对照组(76.4%),差异具有统计学意义(P<0.05);治疗后,两组患者血清MDA及MPO水平均降低,而SOD水平均升高,差异具有统计学意义(P<0.05);与对照组比较,治疗后研究组患者血清MDA及MPO水平较低,而SOD水平较高,差异具有统计学意义(P<0.05)。治疗后,两组患者血清HDL-C水平均升高,而LDL-C,TC及TG水平均降低,差异具有统计学意义(P<0.05);与对照组比较,治疗后研究组患者血清HDL-C水平较高,而LDL-C,TC及TG水平较低,差异具有统计学意义(P<0.05)。与治疗前比较,两组患者治疗后LVEDD及LVESD均降低,而LVEF均升高,差异具有统计学意义(P<0.05);与对照组比较,研究组患者治疗后LVEDD及LVESD较低,而LVEF较高,差异具有统计学意义(P<0.05)。结论:依折麦布联合阿托伐他汀治疗冠心病的临床疗效显著,能够降低患者血脂水平,改善氧化应激反应及心功能,值得临床推广应用。 |
英文摘要: |
ABSTRACT Objective: To investigate the effects of ezetimibe and atorvastatin on the oxidative stress and blood lipid levels in pa- tients with coronary heart disease and its clinical efficacy. Methods: 144 cases with coronary heart disease who were treated in our hospi- tal from August 2013 to August 2016 were selected and randomly divided into the control group and the study group, with 72 cases in each group. The patients in the control group were treated with atorvastatin and nitroglycerin, while the patients in the study group were treated with atorvastatin and ezetimibe. Then the serum levels of peroxidase (MPO), propylene glycol (MDA), superoxide dismutase (SOD), total cholesterol (TC), glycerin three greases (TG), low density lipoprotein (LDL-C) and high density lipoprotein (HDL-C), heart functions and clinical curative effect between the two groups were observed and compared before and after the treatment. Results: The total clinical effective rate in the study group was 87.5%, which was higher than 76.4% in the control group, and the difference was statis- tically significant (P<0.05); After the treatment, the serum levels of MDA and MPO decreased in the two groups, while the SOD in- creased, and the differences were statistically significant (P<0.05); Compared with the control group after treatment, the serum levels of MDA and MPO were lower in the study group, and the SOD was higher, and the differences were statistically significant (P<0.05); After treatment, the serum levels of HDL-C increased in the two groups, while the levels of LDL-C, TC and TG decreased, and the differences were statistically significant (P<0.05); Compared with the control group after treatment, the serum levels of HDL-C was higher in the study group, and the levels of LDL-C, TC and TG were lower, and the differences were statistically significant (P<0.05); Compared with before treatment, the LVEDD and LVESD decreased in the two groups after the treatment, while the LVEF increased, and the differences were statistically significant (P<0.05); Compared with the control group after treatment, the LVEDD and LVESD were lower in the study group, and the LVEF was higher, and the differences were statistically significant (P<0.05). Conclusion: Ezetimibe and atorvastatin have obvious clinical efficacy on the treatment of coronary heart disease, which can reduce the blood lipid levels of patients, and improve the oxidative stress and heart function, and it is worthy of clinical application. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|